Trial Profile
A Retrospective study of evaluate the impact of kidney function on the outcomes of pazopanib treatment in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2017
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CORE-URO-01
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 22 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology